[Respiratory functions in parkinsonian patients with predominant akinesia during treatment with decarboxylase-blocked L-dopa (author's transl)].
[Respiratory functions in parkinsonian patients with predominant akinesia during treatment with decarboxylase-blocked L-dopa (author's transl)].
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
A plain-language reading has not been prepared for this paper yet.
Original abstract
The effect of decarboxylase (DC)-blocked L-dopa (proportion of 4: 1) on respiratory function was tested by spirometry in 30 patients with Parkinson's disease. It was possible to improve restrictive ventilatory abnormalities of extra-pulmonary origin (weakness of respiratory musculature). Vital capacity (VC) increased by 0.21 litre. Thisincrease was due to a raised inspiratory capacity and thus an increase in the active part of ventilation. Forced expiration volume (FEV1) was improved by 0.32 litre, FEV1/VC remaining unchanged, which demonstrates that the restrictive ventilatory abnormality was affected. Inspiratory volume (VT) and minute volume at constant respiratory rate increased by 0.07 and 1.171, respectively. These results must be interpreted with caution, but they suggest a raised metabolic level with regained mobility during treatment. All quoted results, except those of respiratory rate and minute volume, were statistically significant (2 mu equals 0.01).